ReviewInternational journal of nanomedicine2025
Research Progress of Docetaxel Nano-Drug Delivery System in the Treatment of Breast Cancer.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparation and Evaluation of Docetaxel-Loaded Targeted Poly (β‑amino Ester) - Magnetic Nanoparticles for Chemo‑Magnetodynamic Therapy Under Low‑Frequency Magnetic Fields.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common malignant tumor in women. Docetaxel (DTX), a chemotherapeutic agent derived from paclitaxel (PTX), has received approval from the US Food and Drug Administration (FDA) for the treatment of BC and various other malignancies. Nevertheless, its utility in clinical settings is constrained due to its poor water solubility and low oral bioavailability, dose-dependent toxicity, and a short systemic circulation half-life. Developing nano-drug delivery systems for DTX represents a well-established strategy to overcome these limitations. This review, based on a literature search of the PubMed database from 2019 to 2024 using the keywords "docetaxel", "breast cancer", and "nano-drug delivery system", summarises recent advances in targeted nanomedicine delivery systems for DTX and their application in BC treatment when combined with other delivery therapies. Nano-drug delivery systems encompass passive targeting (such as: nanomicelles, liposomes), active targeting (such as: G protein-coupled oestrogen receptor, integrin protein receptor), physicochemical targeting (such as: magnetic-responsive, temperature-responsive), and combined delivery (such as: photothermal therapy, chemotherapeutic drugs, and active components of traditional Chinese medicine). These systems hold great promise for enhancing DTX bioavailability, improving tumor targeting, and regulating drug release. Furthermore, key challenges limiting clinical translation are analysed. This paper provides a theoretical foundation and practical guidance for rationally designing DTX nanomedicines, accelerating their transition from laboratory research to clinical application and offering new hope for BC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.